Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches

Sophia Adamia, PhD, Daisuke Ogiya, MD PhD, Ivane Abiatari, MD, Sigitas J Verselis, PhD, Michael P. Chu, David M. Dorfman, MD PhD, Linda M. Pilarski, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3079.

https://doi.org/10.1182/blood-2019-131243

Published: 2019

Journal Articles

Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy

Daisuke Ogiya, MD PhD, Lisa Müller, Sigitas J Verselis, PhD, Heiner Schaal, PhD, Ivane Abiatari, MD, Ana M Stenstrom, Catherine A Nicholas, John F Daley, Michael P. Chu, David M. Dorfman, MD PhD, Linda M. Pilarski, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Sophia Adamia, PhD

Blood (2019) 134 (Supplement_1): 1804.

https://doi.org/10.1182/blood-2019-131775

Published: 2019

Journal Articles

Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)

Sophia Adamia, PhD, Sigitas J Verselis, PhD, Teru Hideshima, MD PhD, Michael P. Chu, MD, Shruti Bhatt, PhD, David P. Steensma, MD, Daniel J Deangelo, Richard M. Stone, MD, Daniel G. Tenen, MD, Linda M. Pilarski, PhD, James D. Griffin, MD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2018-99-118501

Published: 2018

Journal Articles

Lenalidomide Maintenance Does Not Negatively Impact Overall and Progression Free Survival Using Lenalidomide-Based Regimens for Multiple Myeloma in First Relapse

Hannah Cherniawsky, BSc,MD, Zack M. Breckenridge, BSc, Irwindeep Sandhu, MD FRCPC, Michael P. Chu, MD, Joanne D. Hewitt, NP, PhD, Ismail Ismail, Andrew R Belch, MD, Linda M. Pilarski, PhD, Tatiana Nikitina, Christopher P. Venner, MD FRCPC

Blood (2018) 132 (Supplement 1): 5643.

https://doi.org/10.1182/blood-2018-99-117705

Published: 2018

Journal Articles

Detection of Minimal Residual Disease in Autograft Is Prognostic of Survival Following Stem Cell Transplant in Multiple Myeloma

Michael P. Chu, MD, Eva Baigorri, Jitra Kriangkum, PhD, Joanne D. Hewitt, NP, PhD, Andrew Belch, Christopher P. Venner, Irwindeep Sandhu, MDFRCPC, Linda M. Pilarski, PhD

Blood (2017) 130 (Supplement 1): 1928.

https://doi.org/10.1182/blood.V130.Suppl_1.1928.1928

Published: 2017

Journal Articles

The Survival Impact of Lenalidomide Maintenance Chemotherapy in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplant and Bortezomib-Based Induction: An Analysis of Real World Data

Hannah Cherniawsky, BSc, MD, Irwindeep Sandhu, MDFRCPC, Michael P. Chu, MD, Joanne D. Hewitt, NP, PhD, Ismail Ismail, Andrew Belch, Linda M. Pilarski, PhD, Tatiana Nikitina, PhD, Christopher P. Venner, MD

Blood (2017) 130 (Supplement 1): 3132.

https://doi.org/10.1182/blood.V130.Suppl_1.3132.3132

Published: 2017

Journal Articles

The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort

Zack M. Breckenridge, BSc, Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Paola Neri, MD, Irwindeep Sandhu, MDFRCPC, Michael P. Chu, MD, Ismail Ismail, Jason Tay, MD FRCPC, Peter Duggan, MD FRCPC, Andrew Belch, Joanne D. Hewitt, NP, PhD, Linda M. Pilarski, PhD, Tatiana Nikitina, Christopher P. Venner

Blood (2017) 130 (Supplement 1): 1859.

https://doi.org/10.1182/blood.V130.Suppl_1.1859.1859

Published: 2017

Journal Articles

Ex Vivo Modeling of Multiple Myeloma Provides Basis for Studying Treatment Combinations and Immunotherapy

Michael P. Chu, MD, Christopher P. Venner, MD, Irwindeep Sandhu, MD, Eva Baigorri, PhD, Jitra Kriangkum, PhD, Joanne D Hewitt, RN, BSN, NP, Andrew Belch, Linda M. Pilarski, PhD

Blood (2016) 128 (22): 2113.

https://doi.org/10.1182/blood.V128.22.2113.2113

Published: 2016

Journal Articles

In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort

Christopher P. Venner, MD, Nizar J Bahlis, MD, Paola Neri, MD PhD, Irwindeep Sandhu, MD, Peter Duggan, MD, Andrew Belch, MD, Joanne D Hewitt, RN, BSN, NP, Linda M. Pilarski, PhD, Tatiana Nikitina, Victor H Jimenez-Zepeda, MD

Blood (2015) 126 (23): 4261.

https://doi.org/10.1182/blood.V126.23.4261.4261

Published: 2015

Journal Articles

Functional and Familial Risk of B Lineage Malignancies in Patients Carrying Single Nucleotide Polymorphisms (SNPs) in the Hyaluronan Synthase 1 Gene (HAS1),

Linda M. Pilarski, PhD, Hemalatha Kuppusamy, Jitra Kriangkum, PhD, Amanda Warkentin, Sunita Ghosh, PhD, Spencer B Gibson, PhD, Hlif Steingrimsdottir, MD, Vilhelmina Haraldsdottir, MD, James B Johnston, MD, FRCPC, Helga M Ogmundsdottir, MD, PhD, Andrew R Belch, MD

Blood (2011) 118 (21): 3930.

https://doi.org/10.1182/blood.V118.21.3930.3930

Published: 2011

Journal Articles

Clinically Significant Aberrant HAS1Vb Splicing of the Hyaluronan Synthase 1 Gene ( HAS1 ) Requires a Combination of Mutations and Deletions in Introns 3 and 4 of HAS1 Minigene,

Jitra Kriangkum, PhD, Andrew R Belch, MD, Linda M. Pilarski, PhD

Blood (2011) 118 (21): 3931.

https://doi.org/10.1182/blood.V118.21.3931.3931

Published: 2011

Journal Articles

Second Clones In Molecularly-Defined Biclonal Multiple Myeloma Are Derived From Unrelated B Cells, Can Be Present at High Frequency and Exhibit Chromosomal Abnormalities

Jitra Kriangkum, PhD, Carina Debes Marun, BSc, Sarah Motz, BSc, Andrew Belch, MD, Linda M. Pilarski, PhD

Blood (2010) 116 (21): 2981.

https://doi.org/10.1182/blood.V116.21.2981.2981

Published: 2010

Journal Articles

Cancer-Specific Nuclear Positioning of Translocation Prone Gene Loci In Non-Malignant B-Cells From Patients with Multiple Myeloma

Lorri D. Martin, Jana Harizanova, PhD, George Zhu, Andrew Belch, MD, Sabine Mai, PhD, Linda M. Pilarski, PhD

Blood (2010) 116 (21): 783.

https://doi.org/10.1182/blood.V116.21.783.783

Published: 2010

Journal Articles

Chromosomal Abnormalities in Bone Marrow Lymphocytes of MM Patients

Carina S. Debes Marun, Andrew Belch, MD, Linda M. Pilarski, PhD

Blood (2010) 116 (21): 4045.

https://doi.org/10.1182/blood.V116.21.4045.4045

Published: 2010

Journal Articles

Comparative Whole Transcriptome Shotgun Sequencing (WTSS) of Myeloma at Diagnosis and at Drug-Resistant Relapse.

Tony Reiman, MD, Ryan Morin, PhD, Rodrigo Goya, Tina Wong, Yongjun Zhao, Martin Hirst, Linda M. Pilarski, PhD, Andrew Belch, MD, Marco Marra, PhD

Blood (2009) 114 (22): 603.

https://doi.org/10.1182/blood.V114.22.603.603

Published: 2009

Journal Articles

Molecular Biclonality: Analysis of Clonotypic IgH VDJ Reveals the Frequent Occurrence of a Second Clone in Multiple Myeloma.

Jitra Kriangkum, PhD, Sarah Motz, BSc, Carina Debes Marun, BSc, Andrew Belch, MD, Linda M. Pilarski, PhD

Blood (2009) 114 (22): 1813.

https://doi.org/10.1182/blood.V114.22.1813.1813

Published: 2009

Journal Articles

High Oct-2 Protein Expression Is Associated with Decreased Overall Survival, While High Bob-1 Protein Expression Is Associated with Improved Overall Survival in Myeloma Patients.

Inka Toman, M.Sc., Jonathan Loree, Alex Klimowicz, Ph.D., Nizar J Bahlis, MD, Raymond Lai, MD, PhD, Andrew Belch, MD, Linda M. Pilarski, PhD, Tony Reiman, MD

Blood (2009) 114 (22): 2822.

https://doi.org/10.1182/blood.V114.22.2822.2822

Published: 2009

Journal Articles

Splicing Mutations in the Hyaluronan Synthase I Gene of Patients with Monoclonal Gammopathy of Undetermined Significance.

Hemalatha Kuppusamy, Amanda Warkentin, Andrew Belch, MD, Linda M. Pilarski, PhD

Blood (2009) 114 (22): 2841.

https://doi.org/10.1182/blood.V114.22.2841.2841

Published: 2009

Journal Articles

Splicing Profile of Human Hyaluronan Synthase 1 (HAS1) Is Altered by Mutagenesis of (A/U)GGG Motifs.

Jitra Kriangkum, PhD, Anirban Ghosh, PhD, Amanda A. Warkentin, BSc, Andrew R. Belch, MD, Linda M. Pilarski, PhD

Blood (2009) 114 (22): 2842.

https://doi.org/10.1182/blood.V114.22.2842.2842

Published: 2009

Journal Articles

Analysis of Protein Biology to Increase Efficacy of Aurora Kinase Inhibitors for Multiple Myeloma Therapy.

Robert P. Evans, Ph.D., Kim Laginha, Linda M. Pilarski, PhD, Andrew Belch, MD, Tony Reiman, MD

Blood (2008) 112 (11): 1699.

https://doi.org/10.1182/blood.V112.11.1699.1699

Published: 2008

NARROW

Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches

Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy

Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)

Lenalidomide Maintenance Does Not Negatively Impact Overall and Progression Free Survival Using Lenalidomide-Based Regimens for Multiple Myeloma in First Relapse

Detection of Minimal Residual Disease in Autograft Is Prognostic of Survival Following Stem Cell Transplant in Multiple Myeloma

The Survival Impact of Lenalidomide Maintenance Chemotherapy in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplant and Bortezomib-Based Induction: An Analysis of Real World Data

The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort

Ex Vivo Modeling of Multiple Myeloma Provides Basis for Studying Treatment Combinations and Immunotherapy

In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort

Functional and Familial Risk of B Lineage Malignancies in Patients Carrying Single Nucleotide Polymorphisms (SNPs) in the Hyaluronan Synthase 1 Gene (HAS1),

Clinically Significant Aberrant HAS1Vb Splicing of the Hyaluronan Synthase 1 Gene ( HAS1 ) Requires a Combination of Mutations and Deletions in Introns 3 and 4 of HAS1 Minigene,

Second Clones In Molecularly-Defined Biclonal Multiple Myeloma Are Derived From Unrelated B Cells, Can Be Present at High Frequency and Exhibit Chromosomal Abnormalities

Cancer-Specific Nuclear Positioning of Translocation Prone Gene Loci In Non-Malignant B-Cells From Patients with Multiple Myeloma

Chromosomal Abnormalities in Bone Marrow Lymphocytes of MM Patients

Comparative Whole Transcriptome Shotgun Sequencing (WTSS) of Myeloma at Diagnosis and at Drug-Resistant Relapse.

Molecular Biclonality: Analysis of Clonotypic IgH VDJ Reveals the Frequent Occurrence of a Second Clone in Multiple Myeloma.

High Oct-2 Protein Expression Is Associated with Decreased Overall Survival, While High Bob-1 Protein Expression Is Associated with Improved Overall Survival in Myeloma Patients.

Splicing Mutations in the Hyaluronan Synthase I Gene of Patients with Monoclonal Gammopathy of Undetermined Significance.

Splicing Profile of Human Hyaluronan Synthase 1 (HAS1) Is Altered by Mutagenesis of (A/U)GGG Motifs.

Analysis of Protein Biology to Increase Efficacy of Aurora Kinase Inhibitors for Multiple Myeloma Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only